首页> 外文期刊>Expert opinion on therapeutic targets >The urokinase-type plasminogen activator (uPA) system as a biomarker and therapeutic target in human malignancies
【24h】

The urokinase-type plasminogen activator (uPA) system as a biomarker and therapeutic target in human malignancies

机译:尿激酶型纤溶酶原激活剂(uPA)系统作为人类恶性肿瘤的生物标志物和治疗靶标

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction: The urokinase plasminogen activator (uPA) system, comprising the serine protease uPA, its cognate receptor, uPAR, and two endogenous inhibitors, plasminogen activator inhibitor-1 (PAI-1) and plasminogen activator inhibitor-2 (PAI-2), is a key player in the break-down of extracellular matrix (ECM) and basement membrane. Elevated expression of uPA and uPAR is observed in numerous cancer types and associated with poor prognosis.
机译:简介:尿激酶纤溶酶原激活物(uPA)系统,包括丝氨酸蛋白酶uPA,其同源受体uPAR和两种内源性抑制剂:纤溶酶原激活物抑制剂1(PAI-1)和纤溶酶原激活物抑制剂2(PAI-2),是细胞外基质(ECM)和基底膜分解的关键因素。在许多癌症类型中观察到uPA和uPAR的表达升高,并且与不良预后相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号